KWM
RLMD icon

Keebeck Wealth Management’s Relmada Therapeutics RLMD Stock Holding History

Keebeck Wealth Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$90K Hold
13,000
– – 0.01% 466
2026
Q1 		$90.5K Buy
+13,000
New +$61.5K 0.01% 422

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Keebeck Wealth Management's RLMD Position: Q2 2026 in Review

Keebeck Wealth Management held its Relmada Therapeutics (RLMD) position steady in Q2 2026 at 13,000 shares worth $90K. The position accounts for 0.01% of the portfolio, ranked #466.

Keebeck Wealth Management first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $90.5K in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Keebeck Wealth Management held 13,000 shares of Relmada Therapeutics worth $90K as of Q2 2026.
  • Keebeck Wealth Management left its Relmada Therapeutics share count unchanged in Q2 2026.
  • Relmada Therapeutics made up 0.01% of Keebeck Wealth Management's portfolio in Q2 2026, its #466 holding.
  • Keebeck Wealth Management first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Keebeck Wealth Management's Relmada Therapeutics position peaked at $90.5K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Keebeck Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.